Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 USD | -0.63% | +0.63% | -17.45% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.45% | 190M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Acumen Pharmaceuticals : Credit Suisse Starts Acumen Pharmaceuticals at Outperform with $26 PT, Notes Sole Product's High-Risk, High-Return Potential